Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis

Anthony R Mato, Chadhi Nabhan, Meghan C Thompson, Nicole Lamanna, Danielle M Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D Nasta, Spencer H Bachow, Stephen J Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S Ujjani, Anthony R Mato, Chadhi Nabhan, Meghan C Thompson, Nicole Lamanna, Danielle M Brander, Brian Hill, Christina Howlett, Alan Skarbnik, Bruce D Cheson, Clive Zent, Jeffrey Pu, Pavel Kiselev, Andre Goy, David Claxton, Krista Isaac, Kaitlin H Kennard, Colleen Timlin, Daniel Landsburg, Allison Winter, Sunita D Nasta, Spencer H Bachow, Stephen J Schuster, Colleen Dorsey, Jakub Svoboda, Paul Barr, Chaitra S Ujjani

Abstract

Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia showed that its side effects differ from those of traditional chemotherapy. Reasons for discontinuation in clinical practice have not been adequately studied. We conducted a retrospective analysis of chronic lymphocytic leukemia patients treated with ibrutinib either commercially or on clinical trials. We aimed to compare the type and frequency of toxicities reported in either setting, assess discontinuation rates, and evaluate outcomes. This multicenter, retrospective analysis included ibrutinib-treated chronic lymphocytic leukemia patients at nine United States cancer centers or from the Connect® Chronic Lymphocytic Leukemia Registry. We examined demographics, dosing, discontinuation rates and reasons, toxicities, and outcomes. The primary endpoint was progression-free survival. Six hundred sixteen ibrutinib-treated patients were identified. A total of 546 (88%) patients were treated with the commercial drug. Clinical trial patients were younger (mean age 58 versus 61 years, P=0.01) and had a similar time from diagnosis to treatment with ibrutinib (mean 85 versus 87 months, P=0.8). With a median follow-up of 17 months, an estimated 41% of patients discontinued ibrutinib (median time to ibrutinib discontinuation was 7 months). Notably, ibrutinib toxicity was the most common reason for discontinuation in all settings. The median progression-free survival and overall survival for the entire cohort were 35 months and not reached (median follow-up 17 months), respectively. In the largest reported series on ibrutinib- treated chronic lymphocytic leukemia patients, we show that 41% of patients discontinued ibrutinib. Intolerance as opposed to chronic lymphocytic leukemia progression was the most common reason for discontinuation. Outcomes remain excellent and were not affected by line of therapy or whether patients were treated on clinical studies or commercially. These data strongly argue in favor of finding strategies to minimize ibrutinib intolerance so that efficacy can be further maximized. Future clinical trials should consider time-limited therapy approaches, particularly in patients achieving a complete response, in order to minimize ibrutinib exposure.

Copyright © 2018 Ferrata Storti Foundation.

Figures

Figure 1.
Figure 1.
Outcomes for the entire cohort. Kaplan Meier curves at a median follow-up of 17 months showing (A) progression-free survival (PFS) for the entire cohort and (B) overall survival (OS) for the entire cohort.
Figure 2.
Figure 2.
Outcomes stratified by line of therapy, clinical trial participation, reason for discontinuation and depth of response. Kaplan Meier curves showing outcomes stratified by (A) line of therapy (progression-free survival), (B) clinical trial participation (progression-free survival), (C) reason for discontinuation (progression-free survival), (D) reason for discontinuation (overall survival), and (E) depth of response. CR: complete response; PR: partial response; PR-L: partial response with lymphocytosis; SD: stable disease; PD: progressive disease.

References

    1. Byrd J, Furman R, Coutre S, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–34.
    1. Byrd J, Brown J, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–223.
    1. O’Brien S, Jones J, Coutre S, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, openlabel, multicentre study. Lancet Oncol. 2016;17(10):1409–1418.
    1. Burger J, Tedeschi A, Barr P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia N Engl J Med. 2015;373(25):2425–2437.
    1. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200–211.
    1. Byrd J, Hillmen P, O’Brien S, et al. Long-term efficacy and safety with ibrutinib (ibr) in previously treated chronic lymphocytic leukemia (CLL): up to four years follow-up of the RESONATE study. J Clin Oncol. 2017;35(suppl; abstr 7510).
    1. Maddocks K, Ruppert A, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015; 1(1):80–87.
    1. Woyach J, Ruppert A, Guinn D, et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35(13):1437–1443.
    1. O’Brien S, Furman R, Coutre S, et al. Five- year experience with single-agent ibrutinib in patients with previously untreated and relapsed/refractory chronic lymphocytic leukemia/small Lymphocytic Leukemia. Blood. 2016; 128:233.
    1. Jain P, Thompson P, Keating M, et al. Long- term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123(12): 2268–2273.
    1. Mato A, Nabhan C, Barr P, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128(18):2199–2205.
    1. Parikh S, Chaffee K, Call T, et al. Ibrutinib therapy for chronic lymphocytic leukemia (CLL): an analysis of a large cohort of patients treated in routine clinical practice. Blood. 2015;126(23):2935.
    1. Sandoval-Sus J, Chavez J, Dalia S, et al. Outcomes of patients with relapsed/refractory chronic lymphocytic leukemia after ibrutinib discontinuation outside clinical trials: a single institution experience. Blood. 2015;126:2945.
    1. Winqvist M, Asklid A, Andersson P, et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. Haematologica. 2016;101(12): 1573–1580.
    1. UK CLL Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016;101(12):1563–1572.
    1. Mato A, Nabhan C, Kay N, et al. Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. Br J Haematol. 2016;175(5):892–903.
    1. Bland J, Altman D. Survival probabilities (the Kaplan-Meier method). BMJ. 1998;317(7172):1572.
    1. Hallek M, Cheson B, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. 2008;111(12):5445–5456.
    1. Cheson B, Byrd J, Rai K, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820–2822.
    1. Matthews D, Farewell V. 7 The log-rank or Mantel-Haenszel test for the comparison of survival curves in: Basel S, Karger A, editors. Using and Understanding Medical Statistics 2007:67–75.
    1. Anderson P, Gill R. Cox’s regression model for counting processes: a large sample study. Ann Statist. 1982;10(4):1100–1120.
    1. Thompson PA, O’Brien SM, Wierda WG, et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib- based regimens. Cancer. 2015;121(20): 3612–3621.
    1. O’Brien SM, Byrd JC, Hillmen P, et al. Outcomes with ibrutinib by line of therapy in patients with CLL: analyses from phase III data. J Clin Oncol. 2016;34(15_suppl): 7520.
    1. Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56(10): 2779–2786.
    1. Lampson B, Kasar S, Matos T, et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood 2016;128(12):195–203.
    1. Seymour JF, Ma S, Brander DM, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 1017;18(2): 230–240.
    1. Sharman J, Brander D, Mato A, et al. Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the GENUINE phase 3 study. J Clin Oncol. 2017;35(Supplemental, ASCO abstract 7504).
    1. Hillmen P, Rawstron A, Munir T, et al. The initial report of bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications EHA Oral Presentation June 22–25, Madrid Spain 2017.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren